This page shows the latest renal cell carcinoma news and features for those working in and with pharma, biotech and healthcare.
advanced renal cell carcinoma (a form of kidney cancer). ... that supports the investigation of Keytruda-based combinations for the first-line treatment of advanced renal cell carcinoma,” said Gregory Lubiniecki, associate vice president, oncology
Since then, the immunotherapy has added an array of indications to its arsenal, including approvals for the treatment of head and neck squamous cell carcinoma, classical Hodgkin lymphoma (cHL), cervical cancer, ... renal cell carcinoma (RCC) and a host
Detailed results presented at ESMO 2020 virtual congress. Bristol Myers Squibb has reported positive data for a combination of its PD-L1 inhibitor Opdivo with Exelixis’ Cabometyx in renal cell carcinoma ... Opdivo was the first immune checkpoint
Bavencio (avelumab), in combination with Pfizer’s tyrosine kinase inhibitor Inlyta (axitinib), has been recommended as a first-line treatment for adult patients with advanced renal cell carcinoma (RCC) – the most ... Bavencio is also approved for the
Through their existing portfolio, which supports patients with iMCD, neuroblastoma, renal cell carcinoma (RCC) and oral mucositis (dryness of the mouth and throat) as a common side effect to anticancer therapy,
The partners had been testing Bavencio (avelumab) in untreated, advanced squamous cell carcinoma of the head and neck. ... Merck KGaA/Pfizer’s drug then picked up an approval in first-line, advanced renal cell carcinoma (RCC) last year, the most common
More from news
Approximately 9 fully matching, plus 152 partially matching documents found.
The JAVELIN Renal 101 trial combining Bavencio with Inlyta in previously untreated advanced renal cell carcinoma recently showed itself to be superior in progression- free survival (PFS) compared with Sutent. ... Pfizer also has a considerable stake in
Its first US approval came in April for second-line treatment of renal cell carcinoma (RCC), a prevalent and difficult-to-diagnose cancer, with European regulators giving it the green light ... It showed that Cabometyx can decrease the rate of disease
Collaboration – discovery, development &commercialisation. $965. Exelixis/ Ipsen. Cabozantinib (Renal Cell Carcinoma, Hepatocellular Carcinoma, other indications) and Cometriq (medullary thyroid cancer).
510. SQZ Biotech (US). Roche. Collaboration, licence. B cell engineering platform to discover oncology targets . ... 405. Aveo (US). EUSA. Collaboration, licence. Pre-registration tivozanib for renal cell carcinoma.
Additional GSK products include the VEGFR inhibitor, Votrient (renal cell carcinoma), Tykerb (HER2 metastatic breast cancer), Arzerra (chronic lymphocytic leukaemia) and Promacta (thrombocytopenia). GSK will continue with its immunotherapy and
More from intelligence
Approximately 0 fully matching, plus 6 partially matching documents found.
oncology. Prior to Crescendo, Hashimoto (pictured below, right) led the clinical development of a checkpoint inhibitor in renal cell carcinoma at Roche, and held responsibility for multiple. ... This experience will be crucial as we progress our pipeline
and oncology that we believe will be invaluable as we plan and advance our US registration strategy for tivozanib as a potential treatment for renal cell carcinoma.”.
Humphrey also spent time at Bayer where she oversaw the early and late stage clinical development of the renal cell carcinoma treatment Nexavar (sorafenib).
During this time, he led the launch of Nexavar (sorafenib), which made more than $1bn last year, for the treatment of renal cell carcinoma and hepatocellular carcinoma.
While at Bayer Rosen led launch of Nexavar for renal cell carcinoma and hepatocellular carcinoma. ... Rosen was in charge of Bayer's oncology efforts from 2005 to 2011, where he led the launch of Nexavar (sorafenib) for the treatment of renal cell
More from appointments
Approximately 0 fully matching, plus 5 partially matching documents found.
Therapy Watch CML is part of a wider oncology portfolio which already covers Chronic Lymphocytic Leukaemia (CLL), Non-Hodgkin's Lymphoma (NHL), Melanoma, Non-Small Cell Lung Cancer (NSCLC), Prostate Cancer ... PCa), Renal Cell Carcinoma (RCC) and
This month Therapy Watch Oncology will be expanding its portfolio with the addition of Squamous Cell Carcinoma of the Head and Neck (SCCHN). ... Cell Carcinoma.
In the CABOSUN trial, cabozantinib was compared to sunitinib in treatment naive poor and intermediate risk renal-cell carcinoma (RCC) patients. ... In the CABOSUN trial, cabozantinib was compared to sunitinib in treatment naive poor and intermediate
and renal cell carcinoma (kidney cancer). ... Back then, the UK’s cost-effectiveness watchdog NICE deemed Opdivo too pricey for renal cell carcinoma when taking into account the availability of Pfizer's Inlyta at a markedly lower
More from PMHub
Approximately 1 fully matching, plus 3 partially matching documents found.
Videum Health is a premium video platform that offers brands innovative engagement strategies to reach targeted healthcare audiences on a...